F S&P 500
5,483.25 +6.50 (+0.12%) F Dow Jones
39,153.00 +6.00 (+0.02%) F Nasdaq
19,805.75 +42.50 (+0.22%) E-mini Russell 2000 Index Futur
2,044.40 +4.70 (+0.23%) Petróleo
82.34 +0.17 (+0.21%) Oro
2,376.00 +7.00 (+0.30%)
StageZero Life Sciences Ltd. (SZLSF)
StageZero Life Sciences Ltd.
70 East Beaver Creek Road
Unit 30
Richmond Hill, ON L4B 3B2
Canada
https://www.stagezerolifesciences.com
Sector(es): Healthcare
Industria: Diagnostics & Research
Empleados a tiempo completo: 40
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. James R. Howard-Tripp | Executive Chairman & CEO | 270k | N/D | N/D |
| Dr. Choong-Chin Liew Ph.D. | Co-Founder | 72.96k | N/D | N/D |
Descripción
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman's risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.
Gestión corporativa
La calificación ISS Governance QuickScore de StageZero Life Sciences Ltd. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
